Vaccine immunotherapy with ARNAX induces tumor‐specific memory T cells and durable anti‐tumor immunity in mouse models

Immunological checkpoint blockade therapies benefit a limited population of cancer patients. We have previously shown that vaccine immunotherapy with Toll‐like receptor (TLR)3‐adjuvant and tumor antigen overcomes anti‐programmed death ligand‐1 (PD‐L1) resistance in mouse tumor models. In the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Yohei, Yoshida, Sumito, Takashima, Ken, Ishii‐Mugikura, Noriko, Shime, Hiroaki, Seya, Tsukasa, Matsumoto, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029830/
https://www.ncbi.nlm.nih.gov/pubmed/29791768
http://dx.doi.org/10.1111/cas.13649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029830/
https://www.ncbi.nlm.nih.gov/pubmed/29791768
http://dx.doi.org/10.1111/cas.13649

Ejemplares similares